荷尔蒙避孕药:第二部分-在临床皮肤病学中的使用和相关性
Amit Singal1, Maggie H Zhou2, Marcia S Driscoll3
1Rutgers New Jersey Medical School, Newark, NJ, USA; Department of Dermatology, Weill Cornell Medicine, New York, New York.
Journal of the American Academy of Dermatology
|March 6, 2026
概括
组合口服避孕药 (COCs) 通过降低雄激素水平,有效地治疗和疹等雄激素介导的皮肤疾病. 这篇文章回顾了它们的治疗机制,疗效,以及皮肤病学家的潜在副作用.
科学领域:
- 皮肤病学 皮肤病学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 联合口服避孕药 (COCs) 通过抑制生产和增加性激素结合型球蛋白来降低雄激素水平.
- COCs可以用于治疗雄激素介导的皮肤病.
- 荷尔蒙避孕药也可能通过雌激素和孕激素受体相互作用影响皮肤病症.
研究的目的:
- 讨论激素避孕药在治疗,发和脱发方面的机制和有效性.
- 审查荷尔蒙避孕药的潜在皮肤学副作用.
- 为皮肤科医生指导荷尔蒙避孕药的临床应用.
主要方法:
- 对荷尔蒙避孕机制的现有证据的审查.
- 对COCs针对特定皮肤病的疗效进行临床研究的分析.
- 评估与使用荷尔蒙避孕药相关的皮肤学副作用报告.
主要成果:
- 通过调节雄激素水平,COCs在治疗,发和脱发方面表现出有效性.
- 了解受体相互作用对于预测和管理潜在的皮肤学副作用至关重要.
- 证据支持COC在特定的雌激素依赖性皮肤病中的治疗作用.
结论:
- 荷尔蒙避孕药,特别是COC,为几种雄激素介导的皮肤病提供了可行的治疗选择.
- 皮肤科医生应该意识到这些药物的好处和潜在的不良皮肤学影响.
- 进一步的研究可能会完善使用激素避孕药来优化皮肤病的结果.
关键词:
青 青 青是一种发症 (alopecia) 是一种脱发症.雄性激素性脱发症 (androgenetic alopecia) 是一种导致人脱发的疾病.组合口服避孕药是指口服避孕药.女人发型脱发的原因脱发 脱发 脱发 脱发 脱发 脱发 脱发 脱发 脱发希尔苏特主义 (hirsutism) 是一种口服避孕药是指口服避孕药.更多相关视频
相关概念视频
Birth Control Methods
7.1K
Vasectomy is a surgical form of male sterilization that involves severing and sealing the vasa deferentia, preventing sperm from mixing with semen during ejaculation. Because a vasectomy does not impact the testes' ability to produce testosterone, hormone levels, libido, and sexual function generally remain unchanged. While vasectomy is highly effective in preventing pregnancy, with a success rate near 99.85%, rare cases of recanalization (spontaneous reconnection) can occur. Although...
7.1K
Intrauterine Drug Delivery Systems
69
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
69
Transdermal Drug Delivery Systems
80
Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
80
Target Cell Response to Hormones
6.0K
Hormones intricately bind to receptors on the surface or within target cells, initiating a cascade of cellular responses.
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
6.0K
Hormonal Regulation of the Menstrual Cycle
2.0K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.0K
Hormonal Control of the Ovarian Cycle
7.3K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
7.3K


